INNA
INVALIDATION REVIEWED - NO ACTION REQUIRED BY OFFICE
01/18/2020
Back to search
Official data from USPTO
PATRYS
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: United States
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
60
Latest update
01/18/2020
Trademark type
Word
Nice classes
5, 42
Filing date
06/12/2007
Registration date
04/28/2009
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
04/25/2019
Last transaction
04/25/2019
Responsible office
United States Patent and Trademark Office
Status code
706
Official register
Principal Register
Drawing code
4
Owner type
11
Owner location
South Melbourne, AU
Examiner
STEPHENS,SONYA B
Law office
L90
Current location
GENERIC WEB UPDATE
Holders and representatives
Holders
PATRYS LIMITED
PATRYS LIMITED
Patrys Pty Ltd
Representatives
Mainak H. Mehta Procopio, Cory, Hargreaves & Savitch LLP
Technical classification
Nice Classes
Class 5Class 42
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Pharmaceutical and biotechnological preparations and substances for human medicinal purposesfor the treatment of cancers and autoimmune diseases; veterinary preparations and substances for animal medicinal purposesfor the treatment of cancers and autoimmune diseases; diagnostic preparations for medical use and reagents for medical usefor diagnosis of human diseasessuch as cancer and autoimmune diseases; pharmaceutical and biotechnological preparationsantibodies for the treatment of cancers and autoimmune diseases; pharmaceutical and biotechnological preparationsantibody fragments and antibody conjugates for the treatment of cancers and autoimmune diseases; pharmaceutical and biotechnological preparations for the reconstruction and repair of antibodies for use in the field of cancers and autoimmune diseases; monoclonal antibodies for medical and veterinary usereagents for the diagnosis and prognosis of human and animal diseasessuch as cancer and autoimmune diseases; proteins for medical usefor detecting antibodies; clinical medical reagentsreagents for use in the development of monoclonal antibodies; proteins for medical usefor binding antibodies; reagents for veterinary usereagents for the development of monoclonal antibodies; vaccines; vaccines against cancerviral infection and bacterial infectionvaccines for human use; vaccine adjuvants; medical and veterinary diagnostic reagentsreagents for use in tests for the diagnosis and prognosis of human and animal diseasessuch as cancer and autoimmune diseases; reagents for research purposesdiagnostic reagents for medical research applications; cells for medical or clinical userecombinant human protein production cell lines; proteins for medical use in the field of recombinant DNA technology; biological reagents for medical purposes in the field of molecular biology
Class 42
Scientific research and developmentclinical research and scientific advisory and consultancy services all in relation to antibody production; drug discovery; research and development of vaccinesvaccine screening; scientific research advisory services relating to diagnostic products for diagnosing cancers and autoimmune diseases; diagnostic testing servicesproviding reagent sample testing and diagnostic services for others in the field of science; medical research services; scientific research for medical purposes; pharmaceutical research services; scientific research advisory services comprising the preparation of reports relating to the performance and analysis of research and the outcomes of research in the field of pharmaceuticals and biotechnology; biochemicalchemicalmicroscopyspectroscopyphysiologicalhistologicalelectrical analysis of biological tissues for medical research; scientific research and development services for the production of antibodies; scientific research and development services for the discovery and development of proteins that bind to antibodies
Publications
History of USPTO decisions and trademark events.
60 publications found
INPR
PARTIAL INVALIDATION OF REG EXT PROTECTION CREATED
12/25/2019
NA71
NOTICE OF ACCEPTANCE OF SEC. 71 - E-MAILED
04/25/2019
71AG
REGISTERED-SEC.71 ACCEPTED
04/25/2019
ES71
TEAS SECTION 71 RECEIVED
04/09/2019
REM4
COURTESY REMINDER - SEC. 71 (10-YR) E-MAILED
04/28/2018
RNWL
INTERNATIONAL REGISTRATION RENEWED
06/29/2017
NREP
NEW REPRESENTATIVE AT IB RECEIVED
07/01/2016
INNP
PARTIAL INVALIDATION PROCESSED BY THE IB
09/11/2015
INPS
PARTIAL INVALIDATION OF REG EXT PROTECTION SENT TO IB
08/19/2015
INPC
INVALIDATION PROCESSED
08/19/2015
INPR
PARTIAL INVALIDATION OF REG EXT PROTECTION CREATED
07/06/2015
NA71
NOTICE OF ACCEPTANCE OF SEC. 71 - E-MAILED
11/06/2014
71AG
REGISTERED-SEC.71 ACCEPTED
11/06/2014
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
10/01/2014
ES71
TEAS SECTION 71 RECEIVED
09/22/2014
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
04/02/2014
NREP
NEW REPRESENTATIVE AT IB RECEIVED
11/29/2013
FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
01/12/2013
ADCH
CHANGE OF NAME/ADDRESS REC'D FROM IB
11/11/2011
FICS
FINAL DISPOSITION NOTICE SENT TO IB
08/10/2009
FIMP
FINAL DISPOSITION PROCESSED
08/10/2009
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
07/28/2009
R.PR
REGISTERED-PRINCIPAL REGISTER
04/28/2009
LIMN
LIMITATION FROM THE IB EXAMINED, NO ACTION IS NEEDED
04/06/2009
LIMG
LIMITATION OF GOODS RECEIVED FROM IB
03/13/2009
PUBO
PUBLISHED FOR OPPOSITION
02/10/2009
NPUB
NOTICE OF PUBLICATION
01/21/2009
PREV
LAW OFFICE PUBLICATION REVIEW COMPLETED
01/08/2009
EXPT
EXPARTE APPEAL TERMINATED
12/27/2008
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
12/19/2008
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
12/18/2008
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
12/18/2008
ERFR
TEAS REQUEST FOR RECONSIDERATION RECEIVED
12/16/2008
EXPI
EX PARTE APPEAL-INSTITUTED
12/16/2008
JURT
JURISDICTION RESTORED TO EXAMINING ATTORNEY
12/16/2008
EXAF
EXPARTE APPEAL RECEIVED AT TTAB
12/16/2008
CHLD
CHANGE OF OWNER RECEIVED FROM IB
12/05/2008
GNS1
NOTIFICATION OF SUBSEQUENT FINAL EMAILED
10/31/2008
GNCF
CONTINUATION OF FINAL REFUSAL E-MAILED
10/31/2008
CNCF
ACTION CONTINUING A FINAL - COMPLETED
10/31/2008
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
09/16/2008
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
09/15/2008
ERFR
TEAS REQUEST FOR RECONSIDERATION RECEIVED
09/15/2008
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
09/15/2008
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
09/15/2008
CNFR
FINAL REFUSAL MAILED
06/23/2008
CNFR
FINAL REFUSAL WRITTEN
06/21/2008
ACEC
AMENDMENT FROM APPLICANT ENTERED
05/06/2008
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
05/06/2008
ALIE
ASSIGNED TO LIE
05/01/2008
PAPER RECEIVED
04/29/2008
RFNT
REFUSAL PROCESSED BY IB
02/08/2008
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
01/16/2008
RFRR
REFUSAL PROCESSED BY MPU
01/16/2008
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
01/16/2008
CNRT
NON-FINAL ACTION WRITTEN
01/15/2008
DOCK
ASSIGNED TO EXAMINER
12/21/2007
NWAP
NEW APPLICATION ENTERED
12/21/2007
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
12/20/2007
Continuous trademark protection
Get notified about every new filing that threatens PATRYS or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.